Literature DB >> 27347130

Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.

Jucimara Colombo1, João Marcos Wolf Maciel2, Lívia Carvalho Ferreira3, Renato Ferreira DA Silva4, Debora Aparecida Pires Zuccari5.   

Abstract

Liver cancer is the sixth most commonly occurring cancer globally, and the main histological type is hepatocellular carcinoma. This type of neoplasia has a poor prognosis due to a high rate of recurrence and intrahepatic metastasis, which are closely are closely associated with the angiogenic process. Vascular endothelial growth factor (VEGF), which is under the control of hypoxia inducible factor-1α (HIF-1α), stimulates the proliferation of endothelial cells and increases cell permeability, promoting the growth, spread and metastasis of tumors. Melatonin, the main hormone secreted by the pineal gland, may have a significant role in tumor suppression and has demonstrated antiangiogenic and antimetastatic effects. The aim of the present study was to analyze the cell viability, migration and invasion, as well as the expression of proangiogenic proteins VEGF and HIF-1α, in HepG2 hepatocarcinoma cells, following treatment with melatonin. Cells were cultured and cell viability was investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression of proangiogenic proteins VEGF and HIF-1α, under conditions of normoxia and hypoxia, was verified using immunocytochemistry and quantified by densitometry. The analysis of the processes of cell migration and invasion was performed in a Boyden chamber. The MTT assay revealed a reduction in cell viability (P=0.018) following treatment with 1 mM melatonin for 24 h. The expression of proangiogenic proteins VEGF and HIF-1α was reduced in cells treated with 1 mM melatonin for 24 h in normoxic (P<0.001) and hypoxic (P<0.001) conditions, compared with the control group and with induced hypoxia alone. The rate of cell migration and invasion was additionally reduced in cells treated with 1 mM melatonin for 48 h when compared with the control group (P=0.496). The results of the present study suggest that melatonin may have an antiproliferative, antiangiogenic and antimetastatic role in hepatocarcinoma cells and may present a novel therapeutic option for the treatment of liver cancer.

Entities:  

Keywords:  HepG2; hypoxia-inducible factor 1α; invasion assay; liver cancer; melatonin; vascular endothelial growth factor

Year:  2016        PMID: 27347130      PMCID: PMC4907066          DOI: 10.3892/ol.2016.4605

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  41 in total

1.  Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells.

Authors:  Juntao Wang; Hongbo Hao; Linli Yao; Xiaodan Zhang; Shidou Zhao; Eng-Ang Ling; Aijun Hao; Gang Li
Journal:  J Pineal Res       Date:  2012-03-08       Impact factor: 13.007

Review 2.  Melatonin signaling and cell protection function.

Authors:  Francesca Luchetti; Barbara Canonico; Michele Betti; Marcella Arcangeletti; Francesca Pilolli; Marta Piroddi; Laura Canesi; Stefano Papa; Francesco Galli
Journal:  FASEB J       Date:  2010-06-09       Impact factor: 5.191

3.  Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.

Authors:  Martina Margheri; Nicola Pacini; Alessia Tani; Daniele Nosi; Roberta Squecco; Aida Dama; Erico Masala; Fabio Francini; Sandra Zecchi-Orlandini; Lucia Formigli
Journal:  Eur J Pharmacol       Date:  2012-02-21       Impact factor: 4.432

Review 4.  The role of hypoxia-induced factors in tumor progression.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2004

5.  Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia.

Authors:  Shi-Young Park; Won-Jun Jang; Eui-Yeun Yi; Ji-Yeong Jang; Yunjin Jung; Joo-Won Jeong; Yung-Jin Kim
Journal:  J Pineal Res       Date:  2010-03       Impact factor: 13.007

6.  Downregulation of matrix metalloproteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice.

Authors:  Amartya Mishra; Sumit Paul; Snehasikta Swarnakar
Journal:  Biochimie       Date:  2011-02-24       Impact factor: 4.079

7.  Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.

Authors:  Dirk Vordermark; Anja Kaffer; Susanne Riedl; Astrid Katzer; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

8.  Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells.

Authors:  Min Dai; Peilin Cui; Minghua Yu; Jianqun Han; Hongwei Li; Ruijuan Xiu
Journal:  J Pineal Res       Date:  2008-03       Impact factor: 13.007

9.  Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.

Authors:  Yasumasa Shirouzu; Eduard Ryschich; Olga Salnikova; Vachtang Kerkadze; Jan Schmidt; Guido Engelmann
Journal:  J Surg Res       Date:  2008-08-27       Impact factor: 2.192

Review 10.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.

Authors:  S J Schoenleber; D M Kurtz; J A Talwalkar; L R Roberts; G J Gores
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

View more
  17 in total

Review 1.  Melatonin as an anti-inflammatory agent in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; A H Rezaeyan; A Salajegheh; S Rezapoor
Journal:  Inflammopharmacology       Date:  2017-03-02       Impact factor: 4.473

Review 2.  Melatonin and its mechanism of action in the female reproductive system and related malignancies.

Authors:  Maryam Ezzati; Kobra Velaei; Raziyeh Kheirjou
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

Review 3.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

4.  Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.

Authors:  Youliang Wu; Dapeng Yun; Yingjie Zhao; Yuqi Wang; Ruochuan Sun; Qiang Yan; Shangxin Zhang; Mingdian Lu; Zhen Zhang; Daru Lu; Yongxiang Li
Journal:  Oncotarget       Date:  2017-01-03

5.  Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation.

Authors:  Li-Jia Bu; Han-Qing Yu; Lu-Lu Fan; Xiao-Qiu Li; Fang Wang; Jia-Tao Liu; Fei Zhong; Cong-Jun Zhang; Wei Wei; Hua Wang; Guo-Ping Sun
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

6.  Melatonin and Hippo Pathway: Is There Existing Cross-Talk?

Authors:  Federica Lo Sardo; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-09-06       Impact factor: 5.923

Review 7.  Melatonin as a potential inhibitory agent in head and neck cancer.

Authors:  Chia-Ming Yeh; Shih-Chi Su; Chiao-Wen Lin; Wei-En Yang; Ming-Hsien Chien; Russel J Reiter; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-09

8.  Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas.

Authors:  Lu Ao; Li Li; Huaqin Sun; Huxing Chen; Yawei Li; Haiyan Huang; Xianlong Wang; Zheng Guo; Ruixiang Zhou
Journal:  BMC Gastroenterol       Date:  2020-07-20       Impact factor: 3.067

Review 9.  Melatonin and Cancer Hallmarks.

Authors:  Wamidh H Talib
Journal:  Molecules       Date:  2018-02-26       Impact factor: 4.411

10.  Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds.

Authors:  Ana B Cerezo; Ruth Hornedo-Ortega; M Antonia Álvarez-Fernández; Ana M Troncoso; M Carmen García-Parrilla
Journal:  Nutrients       Date:  2017-03-08       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.